Nuevolution Sitemap Nuevolution
 
Partnering With Nuevolution
Contact
 

 

 

Partnering With Nuevolution


PARTNER OF CHOICE FOR DRUG DISCOVERY

Nuevolution is poised to revolutionise drug discovery and development by utilising its proprietary Chemetics® technology to generate large numbers of potent, structurally diverse, small molecule drug leads to virtually any target in a matter of 3-4 months.

Nuevolution seeks to leverage its broadly applicable Chemetics® drug discovery engine through drug discovery partnerships with leading pharmaceutical and biotechnology companies.

 

PARTNERING STRATEGY

We believe that the sheer number of novel validated drug targets combined with the power and broad utility of Nuevolution’s Chemetics® platform provides an opportunity to develop far more products than any single company can accommodate.

We are therefore interested in establishing collaborations with other companies with access to drug targets and who are seeking state-of-the-art drug discovery and medicinal chemistry capabilities.

We are seeking partnerships in three main categories:

1. Collaborations with companies on targets of their choice, in which we offer access to our technology, access to our libraries and access to our lead generating capabilities with the purpose of generating drug candidates for the partner.

2. Joint venture partnerships in which the partner provides the biological expertise and ideally access to a proprietary target and Nuevolution generates lead candidates to such targets.

3. Licensing agreements or co-development agreements on high affinity ligand pools against targets being worked on by Nuevolution.

 

LICENSING OPPORTUNITIES

Thrombin Inhibitors

Our in-house Thrombin inhibitor programme has yielded a number of active compounds with completely novel structures. We would now like to further develop these compounds and are seeking a partner interested in the discovery and development of Thrombin inhibitors for either a licensing or co-development agreement.

Renin Inhibitors

Our in-house Renin inhibitor programme has yielded many novel and very potent compounds which currently are being progressed into early ADME studies. We would like to further develop these compounds in collaboration with a partner under either a licensing or co-development agreement.

Contacts

Alex Haahr Gouliaev, Ph.D.

Chief Executive Officer

Mads Nørregaard-Madsen, Ph.D.

Director of Lead Discovery

   
 

 

 

 
Nuevolution Sitemap Nuevolution info@nuevolution.com